Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 6785 - 6792 of 12092 results
Upcoming Opinion in ITC Expected To Provide Important Guidance on FRAND and SEPs
September 5, 2017| Blog| Viewpoint
Trump Administration Rescinds the Deferred Action for Childhood Arrivals (“DACA”) Program
September 5, 2017| Alert| Viewpoint
Employers Receive Important Overtime Law News Just Before Labor Day
September 1, 2017| Blog| Viewpoint
D.C. Circuit Holds Cyber-Theft of Customers’ Medical Identifying Information Created Sufficient Increased Risk of Harm to Establish Standing
September 1, 2017| Blog| Viewpoint
Upcoming decisions will reveal whether the ITC still welcomes standard essential patents
September 1, 2017| News
The Bermuda Form: Can ARIAS Disrupt the Traditional Model?
September 1, 2017| News
Managing Employee Benefits in The Face of Technological Change
September 1, 2017| News
NY Federal Court Dismisses Case Against Subsidies for Nuclear Energy
August 31, 2017| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|